| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 09/29/2010 | EP2231633A1 Antitumoral compounds |
| 09/29/2010 | EP2231630A1 Tosylate salt of trans-n-isobutyl-3-fluoro-3- [3-flu0r0-4- (pyrrolidin-1-yl-methyl) -phenyl]cyclobut anecarboxamide |
| 09/29/2010 | EP2231629A1 Modulators for amyloid beta |
| 09/29/2010 | EP2231628A1 Inhibitors of cytochrome p450 |
| 09/29/2010 | EP2231626A1 Isothiazolidine 1,1-dioxide and tetrahydro-2h-1,2-thiazine 1,1-dioxide derivatives as p2x7 modulators |
| 09/29/2010 | EP2231625A1 Thiazole and oxazole kinase inhibitors |
| 09/29/2010 | EP2231624A2 Triazines and related compounds having antiviral activity, compositions and methods thereof |
| 09/29/2010 | EP2231623A1 5-phenyl-lh-benz0 [e] [1, 4] diazepine compounds substituted with an hydroxamic acid group as histone deacetylase inhibitors |
| 09/29/2010 | EP2231620A1 Diaminopyridines for the treatment of diseases which are characterised by excessive or anomal cell proliferation |
| 09/29/2010 | EP2231619A1 Inhibitors of stearoyl-coa desaturase |
| 09/29/2010 | EP2231618A1 Solid forms of (s)-2-amino-3-(4-(2-amino-6-((r)-2,2,2-trifluoro-1-(3'-methoxybiphenyl-4-yl)ethoxy)pyrimidin-4-yl)phenyl)propanoic acid and methods of their use |
| 09/29/2010 | EP2231617A1 Benzimidazole compounds |
| 09/29/2010 | EP2231615A1 Cannabinoid receptor modulators |
| 09/29/2010 | EP2231611A1 Novel 2-pyrrolidinyl-3-amido-6-amino-pyridine derivatives useful as potassium channel activators |
| 09/29/2010 | EP2231610A1 Novel 2-dimethylamino-3-amido-6-amino-pyridine derivatives useful as potassium channel activators |
| 09/29/2010 | EP2231609A1 Novel 2-ethyl-methyl-amino-3-amido-6-amino-pyridine derivatives useful as potassium channel activators |
| 09/29/2010 | EP2231608A1 Novel 2-diethylamino-3-amido-6-amino-pyridine derivatives useful as potassium channel activators |
| 09/29/2010 | EP2231603A1 Substituted 3 -hydroxypyridines and pharmaceutical compositions thereof |
| 09/29/2010 | EP2231602A1 Gamma secretase modulators |
| 09/29/2010 | EP2231601A2 Glycine transporter-1 inhibitors |
| 09/29/2010 | EP2231600A1 Carboxamide, sulfonamide and amine compounds for metabolic disorders |
| 09/29/2010 | EP2231599A1 4-[2,3-difluoro-6-(2-fluoro-4-methyl-phenylsulfanyl)-phenyl]-piperidine |
| 09/29/2010 | EP2231598A1 Novel diazeniumdiolate derivatives, method for the preparation thereof and pharmaceutical compositions containing the same |
| 09/29/2010 | EP2231595A1 Phenyl acetic acid derivatives as inflammation modulators |
| 09/29/2010 | EP2231594A2 Potassium ion channel modulators and uses thereof |
| 09/29/2010 | EP2231590A1 Antitumoral compounds |
| 09/29/2010 | EP2231589A2 Aminotetralin compounds as mu opioid receptor antagonists |
| 09/29/2010 | EP2231588A1 Organic salts of -alanine |
| 09/29/2010 | EP2231585A2 3-carboxypropyl-aminotetralin derivatives as mu opioid receptor antagonists |
| 09/29/2010 | EP2231558A1 3,4-substituted pyrrolidine beta-secretase inhibitors for the treatment of alzheimer's disease |
| 09/29/2010 | EP2231282A1 Protein kinase inhibitors and use thereof |
| 09/29/2010 | EP2231281A2 Combination comprising a mek inhibitor and an aurora kinase inhibitor |
| 09/29/2010 | EP2231280A2 Organic compounds |
| 09/29/2010 | EP2231189A1 Drug delivery system for administration of poorly water soluble pharmaceutically active substances |
| 09/29/2010 | EP2231188A2 Use of 5-aminolevulinic acid and derivatives in a solid form for photodynamic treatment and diagnosis |
| 09/29/2010 | EP2231185A1 Methods and compositions for treating liquid tumors |
| 09/29/2010 | EP2231173A1 Nutraceutical composition and methods of use |
| 09/29/2010 | EP2231169A1 Pharmaceutical compositions comprising nanoparticles and a resuspending material |
| 09/29/2010 | EP2231167A2 Modified oligonucleotides for the treatment of hepatitis c infection |
| 09/29/2010 | EP2231166A1 Medium-chain length fatty acids, salts and triglycerides in combination with gemcitabine for treatment of pancreatic cancer |
| 09/29/2010 | EP2231165A1 Method of determining the probability of a therapeutic response in cancer chemotherapy with cardiac glycoside |
| 09/29/2010 | EP2231164A1 Oxysterols for activation of hedgehog signaling, osteoinduction, antiadipogenesis, and wnt signaling |
| 09/29/2010 | EP2231163A1 Compounds and therapeutic use thereof |
| 09/29/2010 | EP2231162A1 Substituted cyclopentanes having prostaglandin activity |
| 09/29/2010 | EP2231161A1 A process of making imatinib |
| 09/29/2010 | EP2231160A1 Tryptamine sulfonamides as 5-ht6 antagonists |
| 09/29/2010 | EP2231159A1 Method of treating arthritis |
| 09/29/2010 | EP2231158A2 Formulations for the treatment of mucositis induced by antitumor or immunosuppressive therapy |
| 09/29/2010 | EP2231157A1 Methods for increasing endothelial progentior cells |
| 09/29/2010 | EP2231156A1 Methods for increasing white blood cells |
| 09/29/2010 | EP2231155A1 Tetrahydroisoquinoline derivatives |
| 09/29/2010 | EP2231154A1 Therapeutic uses of compounds having affinity to the serotonin transporter, serotonin receptors and noradrenalin transporter |
| 09/29/2010 | EP2231153A2 5-oxo-3-pyrrolidinecarboxamide derivatives as p2x7 modulators |
| 09/29/2010 | EP2231152A2 Thienopyranones as kinase inhibitors |
| 09/29/2010 | EP2231151A2 Antifolate compounds for the treatment of melanoma |
| 09/29/2010 | EP2231150A2 Method for treating addiction using quercetin-containing compositions |
| 09/29/2010 | EP2231149A2 Aldh-2 inhibitors in the treatment of psychiatric disorders |
| 09/29/2010 | EP2231148A2 Pharmaceutical composition for the treatment and prevention of cardiac disease |
| 09/29/2010 | EP2231146A2 Pharmaceutical composition for the treatment and prevention of glaucoma |
| 09/29/2010 | EP2231145A2 Use of glycosylceramides for enhancing the immune response to antigens |
| 09/29/2010 | EP2231144A2 Nanodispersion |
| 09/29/2010 | EP2231143A1 Inhibitors of janus kinases |
| 09/29/2010 | EP2231140A1 Sigma ligands and ikk / nf - kb inhibitors for medical treatment |
| 09/29/2010 | EP2231139A2 Therapeutic formulations based on asiatic acid and selected salts thereof |
| 09/29/2010 | EP2231138A1 Oral pharmaceutical suspension comprising paracetamol and ibuprofen |
| 09/29/2010 | EP2231137A1 Method of modulating membrane potential of a cell |
| 09/29/2010 | EP2231136A1 Compositions comprising hydroxytyrosol and chondroitin and use thereof for the treatment, co-treatment or prevention of inflammatory disorders |
| 09/29/2010 | EP2231133A2 Method and compositions for administering resveratrol and pterostilbene |
| 09/29/2010 | EP2231132A2 Method for preparing nanoparticles based on functional amphiphilic molecules or macromolecules, and the use thereof |
| 09/29/2010 | EP2231131A2 Formulations of organo-platinic compounds in the presence of associative polymers, products thus obtained and uses thereof |
| 09/29/2010 | EP2231128A1 Method of treating dysglycemia and glucose excursions |
| 09/29/2010 | EP2231126A2 Oral dispersable tablet |
| 09/29/2010 | EP2231124A1 Sustained-release pharmaceutical formulation containing an antimuscarinic agent and a wetting agent as well as a process for the preparation thereof |
| 09/29/2010 | EP2231118A2 Suspension comprising non-micronized ezetimibe micro-particles |
| 09/29/2010 | EP2231117A1 Benzodiazepine and/or pharmaceutical composition comprising benzodiazapine derivatives |
| 09/29/2010 | EP2231116A1 Pharmaceutical formulations containing tolperisone |
| 09/29/2010 | EP2231115A1 Transcutaneous pharmaceutical compositions containing a steroid hormone |
| 09/29/2010 | EP2231113A2 Pharmaceutical compound for the prophylaxis and/or symptomatic treatment of cystic fibrosis |
| 09/29/2010 | EP2231108A1 Biodegradable single-phase cohesive hydrogel |
| 09/29/2010 | EP2231105A1 Novel compounds useful in therapeutic and cosmetic methods |
| 09/29/2010 | EP2230943A1 Paediatric fibre mixture |
| 09/29/2010 | EP2230933A1 5-[1'-(decahydro-7-hydroxy-1,1,3a,7-tetramethyl-1h-cyclopropa[a]naphtalen-4-yl)-3'-methylbutyl]-2,4,6-trihydroxy-1,3-benzenedicarboxaldehyde used as drugs |
| 09/29/2010 | EP2230911A1 Patches, formulations, and associated methods for transdermal delivery of alprazolam and other drugs |
| 09/29/2010 | EP2230910A1 Pre-surgical treatment |
| 09/29/2010 | EP2148703B1 Novel agent for releasing active principles in dressings containing at least one fatty substance |
| 09/29/2010 | EP2099797B1 Compounds and compositions as protein kinase inhibitors |
| 09/29/2010 | EP2044058B1 Chemical compounds |
| 09/29/2010 | EP2004641B1 Hiv inhibiting 5-(hydroxymethylene and aminomethylene) substituted pyrimidines |
| 09/29/2010 | EP1968594B1 Treatment of ocular neovascular disorders such as macular degeneration, angiod streaks, uveitis and macular edema |
| 09/29/2010 | EP1966193B1 New salt and polymorph of dpp-iv inhibitor |
| 09/29/2010 | EP1962808B1 Hcv prodrug formulation |
| 09/29/2010 | EP1960398B1 Aryl acetic acid and ester derivatives and their uses as antiinflammatory |
| 09/29/2010 | EP1940409B1 Novel pharmaceutical combinations for the treatment of respiratory disorders |
| 09/29/2010 | EP1917265B1 HETEROARYL-SUBSTiTUTED DIAZATRICYCLOALKANES, METHODS FOR ITS PREPARATION AND USE THEREOF |
| 09/29/2010 | EP1904490B1 Ethanolamine salt of n- (3-methoxy-5-methylpyrazin-2yl) -2- (4- [1 , 3 , 4-0xadiaz0le-2-yl]phenyl) pyridine-3- sulphonamide |
| 09/29/2010 | EP1893200B1 Carbamate derivatives as positive allosteric modulators of metabotropic glutamate receptors |
| 09/29/2010 | EP1863801B1 Benzimidazole derivative and use thereof |
| 09/29/2010 | EP1789398B1 2-amino-quinazoline derivatives useful as inhibitors of b-secretase (bace) |
| 09/29/2010 | EP1776116B1 Veterinary composition comprising an arylpyrazole and a nitroenamine with enhanced antiparasitic activity |
| 09/29/2010 | EP1768979B1 Octahydropyrrolo[2, 3, c]pyridine derivatives and pharmaceutical use thereof |